医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Ascend Performance Materials Announces Price Increase for Intermediate Materials

2020年09月11日 AM01:01
このエントリーをはてなブックマークに追加


 

HOUSTON

Ascend Performance Materials announced today a price increase for intermediate materials.

The price increase takes effect immediately and includes the following terms:

Material

Price Increase

Terms

Hexamethylene Diamine (HMD)

$100/MT

  • As contracts allow
  • Non-contract business – price determined on an order-by-order basis

Adiponitrile (ADN)

$100/MT

  • As contracts allow
  • Non-contract business – price determined on an order-by-order basis

Acrylonitrile (AN)

$85/MT

  • As contracts allow
  • Non-contract business – price determined on an order-by-order basis

Adipic Acid (AA)

$80/MT

  • As contracts allow
  • Non-contract business – price determined on an order-by-order basis

Customers should contact their local sales representative for additional information.

About Ascend Performance Materials

Ascend Performance Materials makes high-performance materials for everyday essentials and new technologies. Our focus is on improving quality of life and inspiring a better tomorrow through innovation. Based in Houston, Texas, and with regional offices in Shanghai, Brussels and Detroit, we are a fully integrated material solutions provider with eight global manufacturing facilities in the United States, Europe and China. Our 2,600-person global workforce makes the plastics, fabrics, fibers and chemicals used to make safer vehicles, cleaner energy, better medical devices, smarter appliances and longer-lasting apparel and consumer goods. We are committed to safety, sustainability and the success of our customers and our communities.

Find out more about Ascend at www.ascendmaterials.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200910005789/en/

CONTACT

Alison Jahn at +1 713-210-9809, ajahn@ascendmaterials.com

同じカテゴリーの記事 

  • 佐賀大学とBostonGeneがEGFR陽性肺癌患者におけるICIの治療効果予測因子を特定するための新規バイオマーカー探索を目的とした研究を発表
  • KBI Biopharma任命Jean-Baptiste Agnus为首席商务官
  • First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome
  • Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
  • LabVantage Celebrates Customer Success with Record Number of Software Deployments in FY 2024